The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
PreviousPrevious
Volume 356:894 March 1, 2007 Number 9
NextNext

Safety and Efficacy of a Recombinant Hepatitis E Vaccine

Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
by Krawczynski, K.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Shrestha, M. P.
Seroprevalence studies suggest that one third of the world's population has been infected with hepatitis E virus (HEV). Infection, especially during pregnancy, is associated with substantial rates of death and complications. No vaccine or specific therapy has been available for the treatment of HEV infection. In this double-blind, placebo-controlled trial involving 2000 subjects in Nepal, the administration of three doses of a novel recombinant HEV vaccine had 95.5% efficacy.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.